Trials / Withdrawn
WithdrawnNCT04151719
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
An Open-Label Extension Study to Evaluate the Safety and Efficacy of Oral Methylnaltrexone Bromide Tablets in Subjects With Advanced Pancreatic Cancer
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label extension study will evaluate the long-term safety and efficacy of oral MNTX in participants with advanced pancreatic cancer (adenocarcinoma) who were previously enrolled in Study SAL-REL-2042 (NCT04083651).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylnaltrexone bromide (MNTX) | Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm. |
Timeline
- Start date
- 2020-02-03
- Primary completion
- 2024-02-03
- Completion
- 2024-02-03
- First posted
- 2019-11-05
- Last updated
- 2021-05-07
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04151719. Inclusion in this directory is not an endorsement.